Literature DB >> 17178097

Role of sphingomyelin and ceramide in the regulation of the activity and fatty acid specificity of group V secretory phospholipase A2.

Dev K Singh1, Laurence R Gesquiere, Papasani V Subbaiah.   

Abstract

We previously showed that group V secretory phospholipase A(2) (sPLA(2)V) is inhibited by sphingomyelin (SM), but activated by ceramide. Here, we investigated the effect of sphingolipid structure on the activity and acyl specificity of sPLA(2)V. Degradation of HDL SM to ceramide, but not to ceramide phosphate, stimulated the activity by 6-fold, with the release of all unsaturated fatty acids being affected equally. Ceramide-enrichment of HDL similarly stimulated the release of unsaturated fatty acids. Incorporation of SM into phosphatidylcholine (PC) liposomes preferentially inhibited the hydrolysis of 16:0-20:4 PC. Conversely, SMase C treatment or ceramide incorporation resulted in preferential stimulation of hydrolysis of 16:0-20:4 PC. The presence of a long chain acyl group in ceramide was essential for the activation, and long chain diacylglycerols were also effective. However, ceramide phosphate was inhibitory. These studies show that SM and ceramide in the membranes and lipoproteins not only regulate the activity of phospholipases, but also the release of arachidonate, the precursor of eicosanoids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178097      PMCID: PMC1857358          DOI: 10.1016/j.abb.2006.11.014

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  37 in total

Review 1.  Potential involvement of type II phospholipase A2 in atherosclerosis.

Authors:  E Hurt-Camejo; G Camejo
Journal:  Atherosclerosis       Date:  1997-07-11       Impact factor: 5.162

2.  Identification and quantification of diacylglycerols in HDL and accessibility to lipase.

Authors:  C Vieu; B Jaspard; R Barbaras; J Manent; H Chap; B Perret; X Collet
Journal:  J Lipid Res       Date:  1996-05       Impact factor: 5.922

3.  Ceramides increase the activity of the secretory phospholipase A2 and alter its fatty acid specificity.

Authors:  Kamen S Koumanov; Albena B Momchilova; Peter J Quinn; Claude Wolf
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

4.  Changes in the phospholipid composition of the arterial cell can result in severe atherosclerotic lesions.

Authors:  F A. Kummerow; L S. Cook; E Wasowicz; H Jelen
Journal:  J Nutr Biochem       Date:  2001-10       Impact factor: 6.048

5.  Purified group X secretory phospholipase A(2) induced prominent release of arachidonic acid from human myeloid leukemia cells.

Authors:  K Hanasaki; T Ono; A Saiga; Y Morioka; M Ikeda; K Kawamoto; K Higashino; K Nakano; K Yamada; J Ishizaki; H Arita
Journal:  J Biol Chem       Date:  1999-11-26       Impact factor: 5.157

6.  Regulation of the activity and fatty acid specificity of lecithin-cholesterol acyltransferase by sphingomyelin and its metabolites, ceramide and ceramide phosphate.

Authors:  Papasani V Subbaiah; Peter Horvath; Srinivasa B Achar
Journal:  Biochemistry       Date:  2006-04-18       Impact factor: 3.162

7.  Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2.

Authors:  Benjamin J Pettus; Alicja Bielawska; Preeti Subramanian; Dayanjan S Wijesinghe; Michael Maceyka; Christina C Leslie; John H Evans; Jessica Freiberg; Patrick Roddy; Yusuf A Hannun; Charles E Chalfant
Journal:  J Biol Chem       Date:  2003-12-15       Impact factor: 5.157

8.  Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans.

Authors:  K Oörni; J K Hakala; A Annila; M Ala-Korpela; P T Kovanen
Journal:  J Biol Chem       Date:  1998-10-30       Impact factor: 5.157

9.  Altered positional specificity of human plasma lecithin-cholesterol acyltransferase in the presence of sn-2 arachidonoyl phosphatidyl cholines. Mechanism of formation of saturated cholesteryl esters.

Authors:  P V Subbaiah; M Liu; P J Bolan; F Paltauf
Journal:  Biochim Biophys Acta       Date:  1992-09-22

10.  Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation.

Authors:  C Ruth Wooton-Kee; Boris B Boyanovsky; Munira S Nasser; Willem J S de Villiers; Nancy R Webb
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-02-12       Impact factor: 8.311

View more
  10 in total

1.  Regulation of plasma cholesterol esterification by sphingomyelin: effect of physiological variations of plasma sphingomyelin on lecithin-cholesterol acyltransferase activity.

Authors:  Papasani Venkata Subbaiah; Xian-Cheng Jiang; Natalia A Belikova; Buzulagu Aizezi; Zhi Hua Huang; Catherine A Reardon
Journal:  Biochim Biophys Acta       Date:  2012-02-18

2.  In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2.

Authors:  Carole Guillaume; Christine Payré; Ikram Jemel; Louise Jeammet; Sofiane Bezzine; Gajendra S Naika; James Bollinger; Philippe Grellier; Michael H Gelb; Joseph Schrével; Gérard Lambeau; Christiane Deregnaucourt
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

3.  Enhanced incorporation of dietary DHA into lymph phospholipids by altering its molecular carrier.

Authors:  Papasani V Subbaiah; Karigowda J Dammanahalli; Peng Yang; Jian Bi; J Michael O'Donnell
Journal:  Biochim Biophys Acta       Date:  2016-05-10

4.  Effect of double bond geometry in sphingosine base on the antioxidant function of sphingomyelin.

Authors:  Papasani V Subbaiah; Debajit Sircar; Ravi S Lankalapalli; Robert Bittman
Journal:  Arch Biochem Biophys       Date:  2008-10-12       Impact factor: 4.013

5.  Modulation of the activity of cytosolic phospholipase A2alpha (cPLA2alpha) by cellular sphingolipids and inhibition of cPLA2alpha by sphingomyelin.

Authors:  Hiroyuki Nakamura; Shigeo Wakita; Akiko Suganami; Yutaka Tamura; Kentaro Hanada; Toshihiko Murayama
Journal:  J Lipid Res       Date:  2009-10-16       Impact factor: 5.922

6.  The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo.

Authors:  Boris Boyanovsky; Melissa Zack; Kathy Forrest; Nancy R Webb
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-01-22       Impact factor: 8.311

7.  Regulation of phosphatidic Acid metabolism by sphingolipids in the central nervous system.

Authors:  Susana J Pasquaré; Virginia L Gaveglio; Norma M Giusto
Journal:  J Lipids       Date:  2010-11-07

8.  Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide.

Authors:  Léon J A Spijkers; Rob F P van den Akker; Ben J A Janssen; Jacques J Debets; Jo G R De Mey; Erik S G Stroes; Bert-Jan H van den Born; Dayanjan S Wijesinghe; Charles E Chalfant; Luke MacAleese; Gert B Eijkel; Ron M A Heeren; Astrid E Alewijnse; Stephan L M Peters
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

Review 9.  Sphingomyelin in high-density lipoproteins: structural role and biological function.

Authors:  Roberto Martínez-Beamonte; Jose M Lou-Bonafonte; María V Martínez-Gracia; Jesús Osada
Journal:  Int J Mol Sci       Date:  2013-04-09       Impact factor: 5.923

Review 10.  Biology of secretory phospholipase A2.

Authors:  Boris B Boyanovsky; Nancy R Webb
Journal:  Cardiovasc Drugs Ther       Date:  2008-10-14       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.